12/20
Headlines

NASDAQ:KPTI

Today’s Watch List : GlycoMimetics, Inc. (NASDAQ:GLYC), Altria Group Inc. (NYSE:MO), Science Applications International Corporation (NYSE:SAIC), Karyopharm Therapeutics, Inc. (NASDAQ:KPTI), Selectica (NASDAQ:SLTC)

Jason Knox03 mins

GlycoMimetics, Inc. (NASDAQ:GLYC) announced that CEO Rachel King will provide a company presentation at the 13th Annual BIO Investor Forum on Tuesday, October 7, 2014 at 1:30 p.m. Eastern Time. GlycoMimetics, Inc. (NASDAQ:GLYC) belongs to Healthcare sector. Its net profit margin is -73.70% and weekly performance is 0.83%. On last trading day company shares ended…

Read More

Top News: Karyopharm Therapeutics (NASDAQ:KPTI), Companhia Siderurgica Nacional (NYSE:SID), NCI Building Systems Inc. (NYSE:NCS), Auxilium Pharmaceuticals (NASDAQ:AUXL), Westbury Bancorp (NASDAQ:WBB)

Mark Doerr03 mins

Karyopharm Therapeutics (NASDAQ:KPTI) major shareholder Marcin Czernik sold 12,795 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $38.07, for a total value of $487,105.65. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major…

Read More

Morning Buzz: Activision Blizzard (NASDAQ:ATVI), Altria (NYSE:MO), Tofutti Brands (NYSEMKT:TOF), Karyopharm Therapeutics, Inc. (NASDAQ:KPTI), ICICI Bank Ltd. (NYSE:IBN)

Ryan Holtz02 mins

Activision Blizzard, Inc. (NASDAQ: ATVI) reported Q2 EPS of $0.06, $0.04 better than the analyst estimate of $0.02. Revenue for the quarter came in at $658 million versus the consensus estimate of $607.75 million. Activision Blizzard, Inc. (NASDAQ:ATVI) belongs to Technology sector. Its net profit margin is 29.10% and weekly performance is -2.61%. On last trading…

Read More

Healthcare most active stocks: Orexigen Therapeutics (NASDAQ:OREX), Express Scripts Holding (NASDAQ:ESRX), Karyopharm Therapeutics Inc (NASDAQ:KPTI), Novavax (NASDAQ:NVAX), Bristol-Myers Squibb (NYSE:BMY)

Jayne Crisman03 mins

According to a statement of Orexigen Therapeutics, Inc. (NASDAQ:OREX), the U.S Food and Drug Administration hasn’t given a green signal to its new drug which helps people in fighting from obesity. One of the spokespersons of the company said,” FDA has delayed its decision on our drug for as much as 3 months. So we…

Read More

Watch List: Neurocrine Biosciences (NASDAQ:NBIX), Karyopharm Therapeutics Inc (NASDAQ:KPTI), Catalyst Pharmaceutical (NASDAQ:CPRX), Supernus Pharmaceuticals Inc (NASDAQ:SUPN), The Medicines Company (NASDAQ:MDCO)

Colin Pettis03 mins

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2014 Global Healthcare Conference in New York City. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock performance was 0.22% in last session and finished the day at $13.94. Traded volume was million shares in the last…

Read More